Genmab A/S has launched a cash tender offer, through its wholly owned subsidiary Genmab Holding II B.V., to acquire all issued and outstanding common shares of Merus N.V. for $97.00 per share. The offer follows a previously announced agreement between the companies. The transaction is not contingent on financing but is subject to certain other conditions. The offer is set to expire at 5:00 p.m. New York City time on December 11, 2025, unless extended, after which a subsequent offering period of at least 10 business days will commence for additional share purchases at the same price.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001134223-en) on October 21, 2025, and is solely responsible for the information contained therein.
Comments